Literature DB >> 8349948

In vitro and in vivo comparative studies on immunosuppressive properties of cyclosporines A, C, D and metabolites M1, M17 and M21.

N Sadeg1, C Pham-Huy, P Rucay, S Righenzi, O Halle-Pannenko, J R Claude, H Bismuth, H T Duc.   

Abstract

Cyclosporine A (CsA) and its major metabolites: M1, M17 and M21 and two analogues: cyclosporines C (CsC) and D (CsD), were studied for their capacity to interfere with different in vitro activation pathways. Their inhibition potentials against the reaction of Graft-versus-Host (GvH) were also studied. The results showed: CsA, CsC and metabolite M17 were the most active compounds upon the inhibition of lymphocyte proliferation induced by different mitogens (ConA, PHA, PWM) and also on the proliferation of mixed lymphocyte cultures (MLC). The same results were observed concerning the direct activation by protein kinase C using a combined action of phorbol ester + calcium ionophore. In vivo using local GvH reaction, CsA and CsC proved more active than M17 in the two different combinations: H-2d --> (H-2b x H-2d)F1 and H-2k --> (H-2b x H-2k)F1 CsD and two metabolites M1 and M21 showed no or weak immunosuppressive effects. Overall, the immunosuppressive potency of six compounds could be schematized as: CsA > or = CsC > M17 > M1 > or = CsD > M21.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349948     DOI: 10.3109/08923979309025992

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  7 in total

1.  Cyclosporin C is the main antifungal compound produced by Acremonium luzulae.

Authors:  M Moussaïf; P Jacques; P Schaarwächter; H Budzikiewicz; P Thonart
Journal:  Appl Environ Microbiol       Date:  1997-05       Impact factor: 4.792

2.  A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.

Authors:  Feng Yang; Jason M Robotham; Henry Grise; Stephen Frausto; Vanesa Madan; Margarita Zayas; Ralf Bartenschlager; Margaret Robinson; Andrew E Greenstein; Anita Nag; Timothy M Logan; Ewa Bienkiewicz; Hengli Tang
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

3.  In vitro metabolism of cyclosporin A with rabbit renal or hepatic microsomes: analysis by HPLC-FPIA and HPLC-MS.

Authors:  C Pham-Huy; N Sadeg; T Becue; C Martin; G Mahuzier; J M Warnet; M Hamon; J R Claude
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

4.  Reversal of multidrug resistance by novel cyclosporin A analogues and the cyclopeptolide SDZ 214-103 biosynthesized in vitro.

Authors:  K Schwabe; G Steinheider; A Lawen; R Traber; A Hildebrandt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Cyclophilin inhibitors as a novel HCV therapy.

Authors:  Hengli Tang
Journal:  Viruses       Date:  2010-08-05       Impact factor: 5.818

6.  Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir.

Authors:  Javier Carbajo-Lozoya; Yue Ma-Lauer; Miroslav Malešević; Martin Theuerkorn; Viktoria Kahlert; Erik Prell; Brigitte von Brunn; Doreen Muth; Thomas F Baumert; Christian Drosten; Gunter Fischer; Albrecht von Brunn
Journal:  Virus Res       Date:  2014-02-22       Impact factor: 3.303

7.  Validation of a novel UPLC-HRMS method for human whole-blood cyclosporine and comparison with a CMIA immunoassay.

Authors:  Xiaoxue Wang; Wei Qin; Wenqian Chen; Huifang Liu; Dan Zhang; Xianglin Zhang; Pengmei Li
Journal:  Exp Ther Med       Date:  2021-01-07       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.